Human immunodeficiency virus (HIV) related heart disease: A review

Wiener Klinische Wochenschrift

Volumn 117, Issue 3, 2005, Pages 73-81

  Sani, Mahmoud U ^a   Okeahialam, Basil N ^b   Aliyu, Sani H ^c,d   Enoch, David A ^c  

^a AMINU KANO TEACHING HOSPITAL   (Nigeria)

^b UNIVERSITY OF JOS   (Nigeria)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

AIDS; Anti retroviral therapy; Cardiomyopathy; Heart disease; Highly active; HIV infection

Indexed keywords

AMPHOTERICIN B; ANTHRACYCLINE DERIVATIVE; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; INTERFERON; METHOTREXATE; PENTAMIDINE; PRAVASTATIN; PREDNISOLONE; PYRIMETHAMINE; RITONAVIR; SIMVASTATIN; UNINDEXED DRUG; VINCRISTINE; ZIDOVUDINE;

AUTONOMIC DYSFUNCTION; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INDUCED DISEASE; DRUG POTENTIATION; DYSLIPIDEMIA; ENDOCARDITIS; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART METASTASIS; HEART TAMPONADE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS RELATED HEART DISEASE; HYPERTENSION; KAPOSI SARCOMA; LIPOATROPHY; LYMPHOMA; MORBIDITY; MORTALITY; MYOCARDITIS; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; REVIEW; SURVIVAL TIME; VIRUS REPLICATION; VIRUS TRANSMISSION;

HEART DISEASES; HIV INFECTIONS; HUMANS;

EID: 14844289547     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-005-0313-3     Document Type: Review

References (84)

1. Autran B, Gorin I, Leibowitch M, Laroche L, Escande JP, Hewitt J, et al (1983) AIDS in a Haitian woman with cardiac Kaposi's sarcoma and Whipple's disease. Lancet 1: 767-768
2. Barbara G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al (2003) An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 25: 2405-2418
3. Acierno LJ (1989) Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review. J Am Coll Cardiol 13: 1144-1154
4. Levy WS, Simon GL, Rios JC, Ross AM (1989) Prevalence of cardiac abnormalities in human immunodeficiency virus infection. Am J Cardiol 63: 86-89
5. Cammarosano C, Lewis W (1985) Cardiac lesions in acquired immune deficiency syndrome (AIDS). J Am Coll Cardiol 5: 703-706
6. Monsuez JJ, Kinney EL, Vittecoq D, Kitzis M, Rozenbaum W, d'Agay MF, et al (1988) Comparison among acquired immune deficiency syndrome patients with and without clinical evidence of cardiac disease. Am J Cardiol 62: 1311-1313
7. Reilly JM, Cunnion RE, Anderson DW, O'Leary TJ, Simmons JT, Lane HC, et al (1988) Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome. Am J Cardiol 62: 789-793
8. Chen Y, Brennessel D, Walters J, Johnson M, Rosner F, Raza M (1999) Human immunodeficiency virus-associated pericardial effusion: report of 40 cases and review of the literature. Am Heart J 137: 516-521
9. Silva-Cardoso J, Moura B, Martins L, Mota-Miranda A, Rocha-Goncalves F, Lecour H (1999) Pericardial involvement in human immunodeficiency virus infection. Chest 115: 418-422
10. Romeu J, Larrousse E, Sirera G, Rius F, Tor J, Clotet B (1990) Utility of echocardiography in AIDS. Chest 98: 775
11. Hsia J, Ross AM (1994) Pericardial effusion and pericardiocentesis in HIV infection. Am J Cardiol 74: 94-96
12. Barbara G, Di Lorenzo G, Grisorio B, Barbarini G (1998) Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. AIDS Res Hum Retroviruses 14: 1071-1077
13. Heidenreich PA, Eisenberg MJ, Kee LL, Somelofski CA, Hollander H, Schiller NB, et al (1995) Pericardial effusion in AIDS. Incidence and survival. Circulation 92: 3229-3234
14. Anderson DW, Virmani R (1990) Emerging patterns of heart disease in human immunodeficiency virus infection. Hum Pathol 21: 253-259
15. Gowda RM, Khan IA, Mehta NJ, Gowda MR, Sacchi TJ, Vasavada BC (2003) Cardiac tamponade in patients with human immunodeficiency virus disease. Angiology 54: 469-474
16. Zakowski MF, Ianuale-Shanerman A (1993) Cytology of Pericardial effusions in AIDS Patients. Diagn Cytopathol 9: 266-269
17. Currie PF, Boon NA (2003) Immunopathogenesis of HIV-related heart muscle disease: current perspectives. AIDS 17 [Suppl 1]: S21-28
18. Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, et al (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1: 3-14
19. Kaul S, Fishbein MC, Siegel RJ (1991) Cardiac manifestations of acquired immune deficiency syndrome: a 1991 update. Am Heart J 122: 535-544
20. Cohen IS, Anderson DW, Virmani R, Reen BM, Macher AM, Sennesh J, et al (1986) Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med 315: 628-630
21. Herskowitz A, Wu TC, Willoughby SB, Vlahov D, Ansari AA, Beschorner WE, et al (1994) Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 24: 1025-1032
22. De Castro S, d'Amati G, Gallo P, Cartoni D, Santopadre P, Vullo V, et al (1994) Frequency of development of acute global left ventricular dysfunction in human immunodeficiency virus infection. J Am Coll Cardiol 24: 1018-1024
23. Herskowitz A, Vlahov D, Willoughby S, Chaisson RE, Schulman SP, Neumann DA, et al (1993) Prevalence and incidence of left ventricular dysfunction in patients with human immunodeficiency virus infection. Am J Cardiol 71: 955-958
24. Lewis W (1989) AIDS: Cardiac findings from 115 autopsies. Prog Cardiovasc Dis 32: 207-215
25. Currie PF, Jacob AJ, Foreman AR, Elton RA, Brettle RP, Boon NA (1994) Heart muscle disease related to HIV infection: prognostic implications. BMJ 309: 1605-1607
26. Humbert M, Monti G, Fartoukh M, Magnan A, Brenot F, Rain B, et al (1998) Platelet derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 11:554-559
27. Jacob AJ, Sutherland GR, Bird AG, Brettle RP, Ludlam CA, McMillan A, et al (1992) Myocardial dysfunction in patients infected with HIV: prevalence and risk factors. Br Heart J 68: 549-553
28. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Stare TJ, Bricker JT, et al (1998) Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group. Circulation 97: 1246-1256
29. Sonnenblick M, Rosenmann D, Rosin A (1990) Reversible cardiomyopathy induced by interferon. BMJ 300: 1174-1175
30. Barbara G, Di Lorenzo G, Soldini M, Giancaspro G, Grisorio B, Pellicelli A, et al (1999) Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). Circ 100: 933-939
31. Fisher SD, Bowles NE, Towbin JA, Lipshultz SE (2003) Mediators in HIV-associated cardiovascular disease: a focus on cytokines and genes. AIDS 17 [Suppl 1]: S29-35
32. Currie PF, Goldman JH, Caforio AL, Jacob AJ, Baig MK, Brettle RP, et al (1998) Cardiac autoimmunity in HIV related heart muscle disease. Heart 79: 599-604
33. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD (1992) Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med 116: 311-313
34. Domanski MJ, Sloas MM, Follmann DA, Scalise PP 3rd, Tucker EE, Egan D, et al (1995) Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. J Pediatr 127: 137-146
35. Tanuma J, Ishizaki A, Gatanaga H, Kikuchi Y, Kimura S, Hiroe M, et al (2003) Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Clin Infect Dis 37: e109-111
36. Lewis W, Simpson JF, Meyer RR (1994) Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and non-competitively by phosphorylated zidovudine. Circ Res 74: 344-348
37. Currie PF, Sutherland GR, Jacob AJ, Bell JE, Brettle RP, Boon NA (1995) A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J 16 [Suppl B]: 15-18
38. Patel RC, Frishman WH (1996) Cardiac involvement in HIV infection. Med Clin North Am 80: 1493-1512
39. Cicalini S, Forcina G, De Rosa FG (2001) Infective endocarditis in patients with human immunodeficiency virus infection. J Infect 42: 267-271
40. Raffanti SP, Fyfe B, Carreiro S, Sharp SE, Hyma BA, Ratzan KR (1990) Native valve endocarditis due to Pseudoallescheria boydii in a patient with AIDS: case report and review. Rev Infect Dis 12: 993-996
41. Kim KK, Facto SM (1987) Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 18: 1293-1296
42. Mesa RA, Edell ES, Dunn WF, Edwards WD (1998) Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 73: 37-45
43. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, et al (1994) Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 89: 2722-2727
44. Aarons EJ, Nye FJ (1991) Primary pulmonary hypertension and HIV infection (letter). AIDS 5: 1276-1277
45. Peters BS, Beck EJ, Coleman DG, Wadsworth MJ, McGuinness O, Harris JR, et al (1991) Changing disease patterns in patients with AIDS in a referral center in the United Kingdom: the changing face of AIDS. BMJ 302: 203-207
46. Moskowitz L, Hensley GT, Chan JC, Adams K (1985) Immediate causes of death in AIDS. Arch Pathol Lab Med 109: 735-738
47. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865-1869
48. Steigman CK, Anderson DW, Macher AM, Sennesh JD, Virmani R (1998) Fatal cardiac tamponade in acquired immunodeficiency syndrome with epicardial Kaposi's sarcoma. Am Heart J 116: 1105-1107
49. Welch K, Finkbeiner W, Alpers CE, Blumenfeld W, Davis RL, Smuckler EA, et al (1984) Autopsy findings in the acquired immunodeficiency syndrome. JAMA 252: 1152-1159
50. Mocroft A, Phillips AN, Lundgren JD (2004) HIV survival benefit associated with earlier antiviral therapy. Ann Intern Med 140: 578-579
51. Biggar RJ, Rabkin CS (1992) The epidemiology of acquired immunodeficiency syndrome-related lymphomas. Curr Opin Oncol 4: 883-893
52. Carbone A, Gaidano G (2001) Acquired immunodeficiency syndrome-related cancer. A study model for the mechanisms contributing to the genesis of cancer. Eur J Cancer 37: 1184-1187
53. Petersen CD, Robinson WA, Kurnick JE (1976) Involvement of the heart and pericardium in malignant lymphomas. Am J Med Sci 272: 161-165
54. Dalli E, Quesada A, Paya R (1990) Cardiac involvement by non-Hodgkin's lymphoma in acquired immunodeficiency syndrome. Int J Cardiol 26: 223-225
55. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186-1191
56. Bharati S, Joshi VV, Connor EM, Oleske JM, Lev M (1989) Conduction system abnormalities in children with acquired immunodeficiency syndrome. Chest 96: 406-413
57. Wharton JM, Demopulos PA, Goldschlager N (1987) Torsades de pointes during administration of pentamidine isethionate. Am J Med 83: 571-576
58. Sani MU, Okeahialam BN, Ukoli CO (2004) Electrocardiographic abnormalities in Nigerian AIDS patients. Trop Card 30: 3-6
59. Craddock C, Pasvol G, Bull R, Protheroe A, Hopkin J (1987) Cardiorespiratory arrest and autonomic neuropathy in AIDS. Lancet 2: 16-18
60. Joshi VV, Pawel B, Connor E, Sharer L, Oleske JM, Morrison S, et al (1987) Arteriopathy in children with acquired immunodeficiency syndrome. Pediatr Pathol 7: 261-275
61. Paton P, Tabib A, Loire R, Tete R (1993) Coronary artery lesions and human immunodeficiency virus infection. Res Virol 144: 225-231
62. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, et al ( 1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-70
63. Johnson RM, Barbarini G, Barbara G (2003) Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients. AIDS 17 [Suppl 1]: S77-82
64. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099
65. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S, AI424-007 Clinical Trial Group (2003) Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr 32: 18-29
66. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al (2003) Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179-1193
67. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al (2003) Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003
68. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al (2004) 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292: 191-201
69. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702-710
70. Marks C, Kuskov S (1995) Pattern of arterial aneurysms in acquired immunodeficiency syndrome. World J Surg 19: 127-132
71. Kaminski HJ, Katzman M, Wiest PM, Ellner JJ, Gifford DR, Rackley R, et al (1988) Cardiomyopathy associated with the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr 1: 105-110
72. Volberding PA, Murphy RL, Barbara G, Barbarini G, Bruno R, Cirelli A, et al (2003) The pavia consensus statement. AIDS 17 [Suppl 1]: S170-179
73. Steger G, Dittrich C, Eichler HG, Flener R, Moser K (1987) Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma. Wien Klin Wochenschr 99: 120-123
74. Dezube BJ, Pantanowitz L, Aboulafia DM (2004) Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 14: 236-238
75. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, et al (2004) Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 18: 485-493
76. Tavio M, Nasti G, Spina M, Errante D, Vaccher E, Tirelli U (1998) Highly active antiretroviral therapy in HIV-related Kaposi's sarcoma. Ann Oncol 9: 923
77. Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, et al (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 16: 2445-2451
78. Fridrik MA, Geit M, Wahl G, Ehrengruber A, Simma R, Hopfel I, et al (1998) Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma. Wien Klin Wochenschr 110: 15-19
79. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al (2001) Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 19: 2171-2178
80. Anderson KM, Wilson PW, Odell PM, Kannel WB (1991) An updated coronary risk profile. A statement for health professionals. Circulation 83: 356-362
81. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37: 613-627
82. van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, et al (2001) Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100
83. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, et al (2002) Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 288: 207-215
84. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, et al (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363: 429-438